<DOC>
	<DOCNO>NCT02174861</DOCNO>
	<brief_summary>To assess long-term safety efficacy AMG 334 .</brief_summary>
	<brief_title>A Study Assess Long-term Safety Efficacy AMG 334 Chronic Migraine Prevention .</brief_title>
	<detailed_description>This multicenter , open-label study ass long-term safety efficacy AMG 334 . All subject receive open-label AMG 334 subcutaneous ( SC ) dose periodically 13 month follow safety follow- visit .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>1 . Subject provide informed consent prior initiation studyspecific activities/procedures 2 . Completed 12week study visit end IP early doubleblind treatment period AMG 334 20120295 parent study , appropriate continue treatment . 1 . Development unstable clinically significant medical condition , laboratory ECG abnormality follow randomization parent study , opinion investigator , would pose risk subject safety interfere study evaluation , procedures completion . 2 . Systolic blood pressure ( BP ) 160 mm Hg and/or diastolic BP 100 mm Hg great screening/Day 1 . 3 . Subject use exclude concomitant medication week 8 week 12 parent study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>66 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Chronic Migraine</keyword>
</DOC>